ClinicalTrials.gg
RecruitingNCT07287332Updated Feb 6, 2026

BLOOM: Pragmatic Feasibility Trial

An interventional study of Up-front individualized dosing algorithm and Usual Care in Sepsis and Infection, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Sepsis by Mayo Clinic — 2 open to participants now, 4 under way, none of them phase 3. Sepsis · Mayo Clinic.

Planned enrollment
7th of 10
300 · median 354
Started
2026
the only one that year
No phase
6 of 16
1 open now
Registered
16th of 16
by date

Among the 16 studies in Sepsis by Mayo Clinic, this one is the 7th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2026, is one of 6 with no phase, and was the 16th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

2 of the 16 studies in Sepsis by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Sepsis by Mayo Clinic, or all of them as a file.
02

Study summary

The goal of this study is to compare two different ways of dosing cefepime, an antibiotic for very sick patients - the usual approach to dosing or a new dosing method. The new dosing method uses only doses that are available in normal care, but choosing between the different doses is based on more information about the patient's body including their kidney function. The primary purpose of this study is to test how easy it is for healthcare professionals to use the new dosing method and how best to conduct the trial. The study will also assess if the new dosing method helps patients recover faster and reduces side effects.

03

Conditions studied

  • Sepsis
  • Infection

Keywords

  • Beta-lactam antibiotics
  • Sepsis
  • Septic shock
  • Pharmacokinetics
  • Personalized medicine
  • Therapeutic drug monitoring
  • Infectious disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥18 years of age
  • Admitted to one of the ICUs at the study center
  • Prescribed cefepime therapy by the care team

Exclusion criteria

Exclusion Criteria:

  • Individuals will be those with a cephalosporin allergy
  • Received >1 dose of cefepime in the 24 hours before ICU admission
  • Transferred from an external hospital without compatible EHR
  • Does not have a cystatin C and a creatinine available for drug dosing
  • Acute kidney injury stage 2 or higher
  • Receiving renal replacement therapy
  • Treated with extracorporeal membrane oxygenation
  • Undergoing molecular adsorbent recirculating therapy at the time of beta-lactam initiation
  • Pregnant
  • Incarcerated
  • Declined Minnesota research authorization
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Up-front individualized dosing algorithm

    Clinical decision support to encourage use of an individualized cefepime dosing algorithm based on eGFRcr-cysC and weight.

    Other: Up-front individualized dosing algorithm

  • Active comparator
    Usual Care

    The standard of care group will receive empiric dosing of cefepime, using an institutional antimicrobial guide based on four categories of eGFRcr.

    Other: Usual Care

Interventions

  • OtherUp-front individualized dosing algorithm

    An individualized cefepime dosing algorithm will be used to determine the cefepime dose and interval. The dose recommendation will be provided using the EHR-prompts to the clinical care team and ordered and/or verified by the ICU pharmacist using an established collaborative practice agreement. As a pragmatic trial, at any point care teams may modify the empiric or subsequent dose based on their clinical judgement.

  • OtherUsual Care

    The standard of care group will receive empiric dosing guided by an institutional antimicrobial guide. Cefepime is typically dosed at 0.5-2 g every 8-24 h according to categorical thresholds of estimated creatinine clearance (eGFRcr). Cystatin C and eGFRcr-cys can be calculated and used at clinicians' discretion to aid in drug dose determination.

06

What researchers measure

Primary outcomes

  1. Proportion of patients screened who qualified for the study

    Number of patients who quality for the study out of total number of patients screened, reported as a percentage

    Time frame: 1 year or once the sample size is achieved

  2. Distribution of qualified patients across care teams

    Number of patients from each ICU care team who qualify for the study

    Time frame: 1 year or once the sample size is achieved

  3. Adherence to dosing recommendations

    Total number of patients randomized to the up-front individualized dosing algorithm who are prescribed the algorithm's recommended dosage

    Time frame: 1 year or once the sample size is achieved

Secondary outcomes

  1. Number of antibiotic-free days

    Number of antibiotic-free days for the first 28 days

    Time frame: 28-days

  2. ICU length of stay

    Number of days of initial ICU stay

    Time frame: 1 year

  3. Proportion of patients who experience new anti-Pseudomonal beta-lactam resistance

    New anti-Pseudomonal beta-lactam resistance which develops within the 6 months following initial treatment

    Time frame: 6 months

  4. Proportion of patients who experience clinical success

    Complete or partial resolution of clinical signs and symptoms attributed to infection across 8 days of therapy.

    Time frame: 8 days

  5. Proportion of patients who experience microbiologic success

    Presumed or documented eradication of causative microorganisms

    Time frame: 8 days

  6. Mortality

    All cause death

    Time frame: 28-days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Barreto EF, Scheetz MH, Chang J, Cole KC, Fogelson LA, Paul J, Jannetto PJ, Gajic O, Rule AD; Beta Lactam Optimization and Outcomes Management (BLOOM) Study Group. Cystatin C-Guided Dosing Nomogram Improves Target Attainment for Cefepime in the Critically Ill. Crit Care Med. 2025 Apr 1;53(4):e941-e952. doi: 10.1097/CCM.0000000000006622. Epub 2025 Feb 27. PubMed 40013864 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Mar 2027, 14 months after the start.

Of 303 non-industry interventional studies with no phase under Sepsis, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 14 months is below that.

Counting every sponsor, half of 326 studies reached it within 22 months; a quarter within 11 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Dec 17, 2025
StartActual
Jan 15, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Jul 2027
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07287332
Lead sponsor
Mayo Clinic
Responsible party
Erin Barreto (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Dec 17, 2025
Start date
Jan 15, 2026
Primary completion
Mar 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Feb 6, 2026

Study contacts

Gerald W. Flaby Jr., LRT, RRT
Contact
flaby.gerald@mayo.edu
507-422-3462
Erin Barreto, PharmD, PhD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion